Background: Lung cancer treatment has become increasingly dependent upon
Introduction
Expression of programmed death-ligand 1 (PD-L1) on tumor cells allows them to evade immune effector mechanisms. Modulation of the PD-1 axis has rapidly emerged as a promising therapeutic approach in heavily pre-treated cancer patients across multiple tumor types (1) (2) (3) (4) . Recently, anti PD-1 axis agents pembrolizumab, nivolumab, and atezolizumab have gained approval as single agents in recurrent lung cancer (5) (6) (7) (8) (9) .
Thus far these agents appear to have superior toxicity profiles, sustained progressionfree responses, and improved overall survival compared to cytotoxic chemotherapy.
Unfortunately, not all patients respond to anti PD-1 axis therapeutics. Therefore, paralleling PD-1 axis clinical development is the need for biomarkers to predict response and toxicity. For example, in recent clinical trials of the checkpoint inhibitors nivolumab and pembrolizumab, the mortality risk for patients treated with either agent was lower among patients in whom PD-L1 expression was identified in biopsy specimens (5) (6) (7) (8) . As a result, profiling for PD-L1 in solid tumor tissue biopsies has become increasingly incorporated into the treatment paradigm for metastatic lung cancer.
Currently lung cancer profiling is dependent upon invasive biopsies to obtain tumor tissue. Not only do invasive procedures expose patients to risks for complications (e.g. pneumothorax, bleeding) (10) , but the scheduling of biopsies can impose significant treatment delays and logistical challenges for patients. Furthermore, heterogeneity among tumor foci may result in discordant responses to systemic therapy. Clinicians often repeat biopsies to optimize their approach to resistant disease. As a result, there is increasing interest in tumor profiling through peripheral blood analysis to avoid the hazards and inconvenience of invasive (potentially multiple) biopsy procedures.
Circulating tumor cells (CTC) have been studied using a diverse array of platforms with distinct strategies to enrich and evaluate the populations of interest. Most commonly, CTC assays impose a positive or negative selection step for enrichment that narrows the populations of circulating cell species that are able to be studied. Enrichment-free technologies, such as automated digital microscopy and computational pathology, image and categorize all nucleated cells and allow a broad array of circulating cell types to be analyzed. Because immunohistochemistry studies of tumor biopsies have identified PD-L1 expression within a variety of tumor and tumor-associated cell types, (11) the non-selection based digital microscopy approach represents an ideal platform to study PD-L1 expression among the broad array of cell types in the peripheral blood.
Materials and Methods

Patient Selection
The patients in the current study represent a subset of a prospective multi-institutional study to evaluate a novel, non-enrichment rare blood cell detection platform (EPIC Sciences) in a lung cancer population (NCT01830426). The parent study enrolled patients who were suspected to have clinical stage I-IV primary lung cancer by imaging, prior to undergoing a procedure for tissue confirmation from 3 institutions (Yale New Haven Hospital, Billings Clinic, and University of California, San Diego). Patients with a prior history of malignancy were excluded. All patients were consented according to an
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Institutional Review Board protocol approved at the three respective institutions and in accordance with the Declaration of Helsinki.
This current analyses represent secondary outcome measures of the original study. In order to maximize the potential utility of PD-L1 as a biomarker, the study was limited to a prognostic subset. More specifically, the current lung cancer subset was restricted to only those patients with: 1) confirmed primary non-small cell lung cancer (NSCLC), because NSCLC represented the majority population in our dataset (95%) and the bulk of the clinical experience with anti-PD-L1 therapy has been with NSCLC patients, 2) complete staging data, and 3) longitudinal follow-up. As an exploratory analysis, 6 patients with small cell carcinoma were evaluated. PD-L1 positive CCAMs were identified in 3 of the patients.
Two populations were used for controls. First a cohort of "healthy controls" was evaluated which included volunteers with no active medical conditions. Recognizing that PD-L1 expression may be influenced by a multitude of factors unrelated to cancer, we developed a second control population comprised of "unhealthy controls." The population of "unhealthy controls" consisted of patients who were included in the parent trial (NCT01830426 described above) under the suspicion of having lung cancer, but were ultimately deemed not to have lung cancer. More specifically, these patients were enrolled based on an abnormality on thoracic imaging that raised suspicion for primary lung cancer yet after biopsy or additional observation, the clinical team determined these patients did not have lung cancer. A "baseline" blood sample was drawn from a peripheral venipuncture (5cc waste) prior to the patient undergoing any invasive procedure for diagnostic, staging, or therapeutic purposes (to avoid contamination from noncancerous epithelial cells resulting from tissue trauma). Blood (7.5 mL) from each subject was collected in Streck (La Vista, Nebraska) tubes and shipped to Epic Sciences within 48 hours and processed immediately on arrival. Erythrocytes were lysed, and approximately 3 million nucleated blood cells were dispensed onto each of 10-16 glass microscope slides and placed at -80°C for long term storage according to methods previously described (12, 13) . Sample processing and testing was conducted in laboratories certified under the Good Laboratory Practices (GLP).
Rare Cell Collection
PD-L1 Assay Development
Anti-PD-L1 rabbit monoclonal antibody from Cell Signaling (clone E1L3N, #13684)(14- Rare cell identification and characterization took place as previously described (13, 17, 18) . In brief, prepared slides were subjected to automated immunofluorescent staining for cytokeratin (CK), DAPI (DNA marker), CD45 (blood lineage marker) and PD-L1. Two slides were stained and evaluated per patient sample with the PD-L1 assay, and processed in tandem with aforementioned high and low PD-L1 expressing cell line control slides. explored effects of epitope availability during apoptotic enzymatic cascade, and were excluded from analyses. For analyses, cell counts per slide were converted to counts per mL of blood via the amount of blood utilized to create patient slides.
Circulating Cells Associated with Malignancy (CCAM)
Many of the identified circulating cells met the field consensus criteria for circulating tumor cells (CTCs): epithelial protein (cytokeratin) expression, absence of blood lineage CD45 expression, and an intact nucleus (19) . On the other hand, many PD-L1 positive, CD45 negative cells in patient samples both contained a nucleus morphologically distinct from surrounding white blood cells, and had cytokeratin expression below the analytical threshold of the assay (Figure 1 ). While these cells were not observed in "healthy control" donor samples, these cells have not been genetically confirmed to be of malignant origin, and we refrained from labeling them as "CTCs". Therefore, throughout this report, we have adopted the nomenclature Circulating Cells Associated with Malignancy (CCAM) to refer to all cells that are 1) nonapoptotic, 2) have a nucleus, 3) are CD45(-), and 4) have cytomorphometric features consistent with circulating tumor cells (size, shape, nuclear to cytoplasm ratio, etc). In other words, the CCAM category includes classic CTCs, as well as cells that meet all other criteria to be a CTC, but don't express cytokeratin.
Statistical Analyses
All statistical analyses were performed with R v3. hazards assumption. The models were refined using a stepwise selection method in which individual covariates had to be significantly associated (p < 0.05) with overall survival in order to be kept in the model. Age did not meet this criterion. All statistical tests were two-sided and a p-value < 0.05 was considered statistically significant.
Results
Distinct Subpopulations of PD-L1(+) Circulating Cells Associated with Malignancy (CCAM)
Of the 112 NSCLC patients studied, PD-L1 (+) CCAMs (see Methods) were detected in 
11
L1(+) CK(+)), while 28 (60%) were negative for cytokeratin (PD-L1(+)CK(-)). Table 1 shows the Profile of CCAMs detected in lung cancer patients.
PD-L1 (+) CCAM Enumeration by Histology and AJCC Stage
The distribution of PD-L1 (+) CCAMs was evaluated across tumor subtypes and AJCC stage (Supplemental Figure S2) . In general, the PD-L1 (+) CCAMs appeared to be more common in patients with stage IV cancer, yet the differences did not reach statistical significance. Table 2 summarizes the 132 blood samples including 112 from cancer patients and 20 from "unhealthy control" patients.
PD-L1(+) CCAMs Associated with Worse Survival
In an effort to better understand the prognostic relevance of the PD-L1(+) CCAM population, the relationship between PD-L1(+) CCAMs and long-term survival was evaluated. The population was stratified using an optimal cutoff (see Methods) of >1.1 PD-L1 (+) CCAM per milliliter as the threshold, (all patients with >1.1 PD-L1(+) CCAM/mL had lung cancer). Kaplan Meier survival curves showed that lung cancer patients with >1.1 PD-L1(+) CCAM/mL (n=14) experienced a worse median survival (16.1 months versus not reached) and worse 2-year survival than those with ≤ 1.1 PD-L1 (+) CCAM/mL (31.2% vs. 78.8%, p = 0.00159) (Figure 2) . In a multivariable Cox PH model adjusting for AJCC staging, expression of >1.1 PD-L1(+) CCAM/mL was an independent predictor of mortality risk (HR = 3.85, 95% CI: 1.64 to 9.09, p = 0.002) (Supplemental Table S1 ). To further characterize the prognostic implications of PD-L1(+) CCAMs, separate Cox PH models were created using progressively higher thresholds of PD-L1(+) CCAMs concentrations (Table 3) . A dose-response relationship was observed, where the mortality risk appeared to increase as the threshold increased (indicating greater numbers of PD-L1(+) CCAMs is associated with worse prognosis), yet the confidence intervals widened as the number of high risk patients declined.
Recognizing the PD-L1(+) CCAMs that are negative for cytokeratin (PD-L1+/CKCCAMs) represent a previously undescribed circulating species, a subsequent analysis was performed by stratifying patients exclusively on the presence or absence of this population of cells. The presence of PD-L1+/CK-CCAMs was associated with a worse prognosis, indicating that this represents a clinically relevant cellular population (Supplemental Figure S3 and Table 4 ). As a supplementary analysis, patients were stratified by the presence or absence of PD-L1 negative cells that met our most stringent criteria of circulating tumor cells (cytokeratin positive CCAMs that were PD-L1 negative), however this population of cells was not found to be prognostic ( Table 4) . In the current study, we report a population of PD-L1(+) cells previously undescribed in lung cancer that share many characteristics with circulating tumor cells (i.e. nucleus present, CD45(-), non-apoptotic, size, shape, nucleus to cytoplasm ratio of CTCs), but do not express cytokeratin. A recent publication has reported similar circulating cells in bladder cancer patients (22) . The study was too small for prognostic interpretation, but single-cell sequencing of these CD45(-), PD-L1(+), cytokeratin-negative cells revealed copy number variations consistent with malignant origin. In both studies, this population was only able to be imaged because the automated digital microscopy platform used to evaluate the rare cell populations (Epic Sciences CTC Detection Platform) did not include a positive or negative selection step. This turned out to be a critically important There is also the possibility that these cells represent a transition in cancer cell phenotype, such as epithelial-mesenchymal transition (EMT). In a case study, utilizing a filtration-enrichment strategy (ISET), Chinen et al reported lung cancer associated cells positive for N-cadherin and negative for CK7 and CK8 (24) . The authors proposed an EMT related mechanism (25, 26) to explain the observed phenomenon. PD-L1 expression and EMT were found to be co-regulated by microRNA-200 in a preclinical model (27) . In breast cancer tissue samples, EMT-like signatures were found to be highly associated with higher PD-L1 expression (28) . A recent study reported detection of CD45(-) / PD-L1(+) / vimentin(+) cells in the peripheral blood of colorectal carcinoma and prostate cancer patients, presumably CTCs that had undergone EMT (29).
Ultimately we refrained from referring to these populations as circulating tumor cells because we recognize the possibility that they are related to malignancy but might not actually be tumor derived. The presence of PD-L1(+) CCAMs was significantly associated with increased 2-year mortality risk. This is consistent with prior reports that have demonstrated a poorer prognosis in patients whose tumors express PD-L1 (30) . Furthermore, high concentrations of non-cell bound (soluble) circulating PD-L1 protein assessed via ELISA assay in 109 cancer patients was previously associated with shorter median survival (18.7 vs. 26.8 months) (31) . We recognize that the prognostic ability of PD-L1(+) CCAM status in the peripheral blood, while significant, is unlikely to change patient care.
Nonetheless, we feel this clinical association provides strong evidence that the PD-L1(+) CCAM population is clinically relevant to the patients, potentially representing PD-L1 expression at some level of the host-tumor interface. Because these samples were collected as a part of a prospective trial, we are not able to compare the PD-L1 expression in the peripheral blood to that of the primary tumors (primary tumors not currently available for profiling). However, we propose that the peripheral blood offers an important perspective of PD-L1 status that is independent of the status of the primary tumor (i.e. if the primary tumor was negative, it is possible that the patient may still benefit from checkpoint inhibitors).
In conclusion, an enrichment-free, whole plasma scanning, rare cell detection platform has enabled the identification of two species of PD-L1 expressing cells in lung cancer patients that appear to be clinically relevant. Further study is warranted to evaluate the relationship between the cellular expression of PD-L1 in the peripheral blood and the efficacy of immunotherapy affecting the PD-1 axis. 
